Fosaprepitant

Chemical formula: C₂₃H₂₂F₇N₄O₆P  Molecular mass: 614.407 g/mol  PubChem compound: 219090

Therapeutic indications

Fosaprepitant is indicated for:

Prevention of nausea and vomiting associated with chemotherapy

Population group: only adults (18 years old or older)

Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Prevention of nausea and vomiting associated with chemotherapy

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in paediatric patients aged 6 months and older.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Fosaprepitant is contraindicated in the following cases:

Pimozide, terfenadine, astemizole, cisapride

at least one of
Pimozide
Cisapride
Terfenadine
Astemizole

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2019: IVEMEND Powder for solution for infusion
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈